Blue Cross/Blue Shield of NJ Initiates Payment for Cambridge Heart MTWA Test; Medical Mutual of Ohio also Establishes MTWA Coverage Policy.

BEDFORD, Mass. -- Cambridge Heart (OTCBB:CAMH) today announced that Horizon Blue Cross/Blue Shield (of New Jersey) has issued a coverage policy for the Company's Microvolt T-Wave Alternans (MTWA) Test making it a covered benefit for those individuals who are being considered for implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death. The Horizon Blue Cross/Blue Shield plan covers 3.2 million patient lives, mostly in New Jersey, and is immediately effective.

Primary prevention candidates for ICDs are individuals who have not experienced a life threatening cardiac arrhythmia. More specifically the coverage considers MTWA medically appropriate as a risk stratification tool to aid in the clinical management of patients often referred to as SCD-HeFT and MADIT II patients (based on two recent ICD studies). These patients exhibit poor pumping efficiency of their hearts as measured by an ejection fraction less than or equal to 35%. The cause may be from ischemic (lack of coronary artery blood flow) or non ischemic causes.

The policy states, "Because of its high negative predictive value, patients who test negative may be at low risk for SCD and thus, unlikely to benefit from ICD implantation. On the other hand, those who test positive or indeterminate may be candidates for further invasive electrophysiologic studies or more aggressive management with eventual ICD placement."

"It is clear from Horizon's coverage policy that their Medical Policy Team understands the value which Microvolt T-Wave Alternans testing can bring to patients, doctors and insurance plans in assuring appropriateness of patient care." stated David Chazanovitz, President and CEO of Cambridge Heart. Mr. Chazanovitz went on to say, "We are encouraged that more private insurance companies are recognizing the need to make risk stratification information available to both the patient and the doctor to help assure the best possible decisions with regard to invasive therapy in this large group of primary prevention patients.

The Company also announced that Medical Mutual of Ohio has initiated coverage for MTWA testing (CPT Code 93025) in circumstances where the predictability of ventricular tachycardia / fibrillation would significantly alter clinical decisions in the management of an individual at risk for sudden cardiac death. Medical Mutual of Ohio covers approximately 1.4 million lives.

About the Cambridge Heat Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

Statements contained in this press release that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.